Tenon Medical Inc (TNON)

Tenon Medical(R) Announces FDA 510(k) Clearance for Catamaran(R) SI Joint Fusion SystemJuly 2, 2026 8:00 AM
ACCESS Newswire~ Updated clearance incorporates various instrument upgrades, as well as per-procedure costs, improving unit economics driven by the reclassification of certain instruments from disposable to reusable status ~~ Clearance reflects Tenon's commitment to continuous innovation and operational efficiency, with reusable instrumentation expected to drive lower capex and logistical spend, contributing positively to gross margins and cash flow ~LOS GATOS, CA / ACCESS Newswire / July 2, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacro-pelvic disorders, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Catamaran® SI Joint Fusion System.The updated clearance incorporates various instrument upgrades, as well as the reclassification of certain instruments from disposable to reusable status. These enhancements are designed to further improve the performance of the Catamaran System while delivering meaningful economic benefits to the Company by eliminating ongoing per-procedure costs previously associated with disposable instrumentation."This 510(k) clearance reflects our ongoing commitment to never-ending refinement of our Catamaran System - not only for the physicians who rely on it and the patients who depend on it, but also for the long-term financial health of our business," said Steven M. Foster, President and CEO of Tenon. "The instrument upgrades advance the procedural performance that our surgeon users have come to expect from the Catamaran platform, and the transition of select instruments from disposable to reusable status is a smart operational improvement that will reduce our per-procedure cost structure and contribute positively to our gross margins going forward. As we continue to drive commercial adoption across our growing portfolio, initiatives like this demonstrate that we are focused on building a sustainable, scalable business."The Catamaran SI Joint Fusion System offers a novel, minimally invasive approach to the sacroiliac joint, utilizing a single, robust titanium implant that stabilizes and transfixes the SI joint along its longitudinal axis. The implant's inferior-posterior surgical approach is designed to navigate away from critical neural and vascular structures and into the strongest cortical bone. Since its national launch in October 2022, there have been over 1,500 Catamaran Fixation Devices implanted in patients throughout the United States suffering from sacroiliac joint disruptions and degenerative sacroiliitis.About Tenon Medical, Inc.Tenon Medical, Inc. is a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders. Tenon was incorporated in the State of Delaware in 2012 and currently offers two systems to treat a diseased sacroiliac joint (the "SI Joint"). The Company has developed The Catamaran™ SI Joint Fusion System that offers a novel, less invasive approach to the SI Joint using a single, robust titanium implant. In August 2025, the Company acquired substantially all of the assets of SiVantage, Inc. and SIMPL Medical, LLC, including the SImmetry+® SI Joint Fusion System, which treats disorders of the SI Joint through a minimally invasive lateral access solution that incorporates well-established orthopedic fusion principles. Since the national launch of The Catamaran System in October 2022, Tenon is focused on three commercial opportunities: 1) primary SI Joint procedures, 2) revision procedures of failed SI Joint implants and 3) SI-Joint fusion adjunct to a spine fusion construct.For more information, please visit www.tenonmed.com. Information on the Company's website does not constitute a part of and is not incorporated by reference into this press release.The Tenon Medical logo shown above, and Catamaran®, PiSIF®, CAT PiSIF®, ETAD®, Posterior Inferior Sacroiliac Fusion®, CAT SIJ Fusion System®, Catamaran SIJ Fusion System®, Catamaran Inferior Posterior Fusion System®, Catamaran Transfixation Fusion System®, Catamaran Transfixation Fusion Device®, SImmetry® are registered trademarks of Tenon Medical, Inc. MAINSAILTM, and SImmetry+ are also trademarks of Tenon Medical, Inc.Safe HarborThis press release contains "forward-looking statements," which are statements related to events, results, activities or developments that Tenon expects, believes or anticipates will or may occur in the future. Forward-looking often contains words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and similar expressions and the negative versions thereof. These forward-looking statements, include, but are not limited to, statements regarding the completion of the Offering, the satisfaction of customary closing conditions related to the Offering and the anticipated use of proceeds therefrom. Such statements are based on Tenon's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. For details on the uncertainties that may cause Tenon's actual results to be materially different than those expressed in any forward-looking statements, please review Tenon's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and updated from time to time in our Form 10-Q filings and in our other public filings on file with the SEC at www.sec.gov statements contain, particularly the information contained in the section entitled "Risk Factors." We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law.IR Contact:
Shannon Devine
203-741-8811
MZ North America
tenon@mzgroup.usSOURCE: Tenon Medical, Inc.View the original press release on ACCESS NewswireOriginal: Tenon Medical(R) Announces FDA 510(k) Clearance for Catamaran(R) SI Joint Fusion System

Tenon Medical, Inc. Announces Closing of $4.2 Million Public OfferingJuly 1, 2026 12:10 PM
ACCESS NewswireLOS GATOS, CA / ACCESS Newswire / July 1, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, announced that it has closed its previously announced public offering of securities as described below for aggregate gross proceeds to the Company of $4.2 million, before deducting placement agent fees and other estimated offering expenses payable by the Company.The offering consisted of 11,052,631 shares of our common stock, par value $0.001 per share (or pre-funded warrants in lieu thereof), together with common stock purchase warrants to purchase up to 13,263,159 shares of common stock (the "Common Warrants"), at a combined public offering price of $0.38 per share of common stock (inclusive of the pre-funded warrant exercise price of $0.001) and accompanying Common Warrants. The number of shares of Common Stock underlying the Common Warrants will be increased to 16,578,949 if the Company effects a reverse stock split.The Company expects to use the net proceeds from the offering for partial repayment of outstanding convertible notes, expansion of the commercial footprint of its product portfolio including training clinicians on current procedures, hiring additional direct sales reps, expansion of its external distribution network, continuing clinical research studies to support reimbursement and coverage efforts, funding research and development including upcoming future launches, and increases to inventory and instrumentation capacities, as well as other marketing activities, working capital and general corporate purposes.WallachBeth Capital LLC acted as sole placement agent in connection with the offering. Sichenzia Ross Ference Carmel LLP acted as legal counsel to the Company and Sheppard, Mullin, Richter & Hampton LLP acted as counsel to WallachBeth Capital LLC.The Common Warrants will be immediately exercisable and will entitle the holder to purchase one share of common stock at an exercise price of $0.38 per share. Each pre-funded warrant will be immediately exercisable, will entitle the holder to purchase one share of common stock at an exercise price of $0.001 per share and may be exercised at any time until exercised in full. The common stock (or pre-funded warrant in lieu thereof) and Common Warrants can only be purchased together in this offering but will be immediately issued separately.The securities described above are being offered by the Company pursuant to a registration statement on Form S-1 (File No.: 333-296952), as amended, previously filed and declared effective by the Securities and Exchange Commission (the "SEC"), and the registration statement on Form S-1MEF (File No.: 333-297142). This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. The offering is being made only by means of a preliminary prospectus and final prospectus that will form a part of the registration statement. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Electronic copies of the prospectus supplements may be obtained, when available, from WallachBeth Capital, LLC, via email at

Bought .3297 ave.

WallachBeth Capital Announces Pricing of Tenon Medical, Inc. $4.2 Million Public OfferingJune 30, 2026 10:00 AM
PR Newswire (US) JERSEY CITY, N.J., June 30, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, has priced a public offering of securities as described below for aggregate gross proceeds to the Company of approximately $4.2 million, before deducting placement agent fees and other estimated offering expenses payable by the Company. The offering consists of up to 11,052,631 shares of our common stock, par value $0.001 per share (or pre-funded warrants in lieu thereof), together with common stock purchase warrants to purchase up to 13,263,159 shares of common stock (the "Common Warrants"), at a combined public offering price of $0.38 per share of common stock (inclusive of the pre-funded warrant exercise price of $0.001) and accompanying Common Warrants.The Company expects to use the net proceeds from the offering for partial repayment of outstanding convertible notes, expansion of the commercial footprint of its product portfolio including training clinicians on current procedures, hiring additional direct sales reps, expansion of its external distribution network, continuing clinical research studies to support reimbursement and coverage efforts, funding research and development including upcoming future launches, and increases to inventory and instrumentation capacities, as well as other marketing activities, working capital and general corporate purposes.WallachBeth Capital LLC is acting as sole placement agent in connection with the offering. Sichenzia Ross Ference Carmel LLP acted as legal counsel to the Company and Sheppard, Mullin, Richter & Hampton LLP acted as counsel to WallachBeth Capital LLC.The Common Warrants will be immediately exercisable and will entitle the holder to purchase one share of common stock at an exercise price of $0.38 per share. Each pre-funded warrant will be immediately exercisable, will entitle the holder to purchase one share of common stock at an exercise price of $0.001 per share and may be exercised at any time until exercised in full. The common stock (or pre-funded warrant in lieu thereof) and Common Warrants can only be purchased together in this offering but will be immediately issued separately.The securities described above are being offered by the Company pursuant to a registration statement on Form S-1 (File No.: 333-296952), as amended, previously filed and declared effective by the Securities and Exchange Commission (the "SEC"), and the registration statement on Form S-1MEF (File No.: 333-297142). This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. The offering is being made only by means of a preliminary prospectus and final prospectus that will form a part of the registration statement. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Electronic copies of the prospectus supplements may be obtained, when available, from WallachBeth Capital, LLC, via email at cap-mkts @shavach, or by standard mail at WallachBeth Capital LLC, Attn: Capital Markets, 185 Hudson St., Suite 1410, Jersey City, NJ 07311, USA.About WallachBeth Capital LLC:WallachBeth Capital offers a robust range of capital markets and investment banking services to the healthcare community, connecting corporate clients with leading institutions, supporting issuers and investors in achieving their financial goals. The firm's experience includes initial public offerings, follow-on issues, PIPE offerings, and private transactions and ATM's.Forward-Looking StatementsThis press release contains "forward-looking statements," which are statements related to events, results, activities or developments that Tenon expects, believes or anticipates will or may occur in the future. Forward-looking often contains words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and similar expressions and the negative versions thereof. These forward-looking statements, include, but are not limited to, statements regarding the completion of the Offering, the satisfaction of customary closing conditions related to the Offering and the anticipated use of proceeds therefrom. Such statements are based on Tenon's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. For details on the uncertainties that may cause Tenon's actual results to be materially different than those expressed in any forward-looking statements, please review Tenon's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and updated from time to time in our Form 10-Q filings and in our other public filings on file with the SEC at www.sec.gov statements contain, particularly the information contained in the section entitled "Risk Factors." We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law. View original content to download multimedia:https://www.prnewswire.com/news-releases/wallachbeth-capital-announces-pricing-of-tenon-medical-inc-4-2-million-public-offering-302814636.htmlSOURCE WallachBeth Capital LLC Original: WallachBeth Capital Announces Pricing of Tenon Medical, Inc. $4.2 Million Public Offering

Tenon Medical, Inc. Announces Pricing of $4.2 Million Public OfferingJune 30, 2026 9:25 AM
ACCESS NewswireLOS GATOS, CA / ACCESS Newswire / June 30, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders, announced that it has priced a public offering of securities as described below for aggregate gross proceeds to the Company of approximately $4.2 million, before deducting placement agent fees and other estimated offering expenses payable by the Company.The offering consists of up to 11,052,631 shares of our common stock, par value $0.001 per share (or pre-funded warrants in lieu thereof), together with common stock purchase warrants to purchase up to 13,263,159 shares of common stock (the "Common Warrants"), at a combined public offering price of $0.38 per share of common stock (inclusive of the pre-funded warrant exercise price of $0.001) and accompanying Common Warrants.The Company expects to use the net proceeds from the offering for partial repayment of outstanding convertible notes, expansion of the commercial footprint of its product portfolio including training clinicians on current procedures, hiring additional direct sales reps, expansion of its external distribution network, continuing clinical research studies to support reimbursement and coverage efforts, funding research and development including upcoming future launches, and increases to inventory and instrumentation capacities, as well as other marketing activities, working capital and general corporate purposes.WallachBeth Capital LLC is acting as sole placement agent in connection with the offering. Sichenzia Ross Ference Carmel LLP acted as legal counsel to the Company and Sheppard, Mullin, Richter & Hampton LLP acted as counsel to WallachBeth Capital LLC.The Common Warrants will be immediately exercisable and will entitle the holder to purchase one share of common stock at an exercise price of $0.38 per share. Each pre-funded warrant will be immediately exercisable, will entitle the holder to purchase one share of common stock at an exercise price of $0.001 per share and may be exercised at any time until exercised in full. The common stock (or pre-funded warrant in lieu thereof) and Common Warrants can only be purchased together in this offering but will be immediately issued separately.The securities described above are being offered by the Company pursuant to a registration statement on Form S-1 (File No.: 333-296952), as amended, previously filed and declared effective by the Securities and Exchange Commission (the "SEC"), and the registration statement on Form S-1MEF (File No.: 333-297142). This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. The offering is being made only by means of a preliminary prospectus and final prospectus that will form a part of the registration statement. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Electronic copies of the prospectus supplements may be obtained, when available, from WallachBeth Capital, LLC, via email at cap-mkts @shavach, or by standard mail at WallachBeth Capital LLC, Attn: Capital Markets, 185 Hudson St., Suite 1410, Jersey City, NJ 07311, USA.About Tenon Medical, Inc.Tenon Medical, Inc., a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders. Tenon was incorporated in the State of Delaware in 2012 and currently offers two systems to treat a diseased sacroiliac joint (the "SI Joint"). The Company has developed The Catamaran™ SI Joint Fusion System that offers a novel, less invasive approach to the SI Joint using a single, robust titanium implant. In August 2025, the Company acquired substantially all of the assets of SiVantage, Inc. and SIMPL Medical, LLC, including the SImmetry+® SI Joint Fusion System, which treats disorders of the SI Joint through a minimally invasive lateral access solution that incorporates well-established orthopedic fusion principles. Since the national launch of The Catamaran System in October 2022, Tenon is focused on three commercial opportunities: 1) primary SI Joint procedures, 2) revision procedures of failed SI Joint implants and 3) SI-Joint fusion adjunct to a spine fusion construct.For more information, please visit www.tenonmed.com. Information on the Company's website does not constitute a part of and is not incorporated by reference into this press release.The Tenon Medical logo shown above, and Catamaran®, PiSIF®, CAT PiSIF®, ETAD®, Posterior Inferior Sacroiliac Fusion®, CAT SIJ Fusion System®, Catamaran SIJ Fusion System®, Catamaran Inferior Posterior Fusion System®, Catamaran Transfixation Fusion System®, Catamaran Transfixation Fusion Device®, SImmetry® are registered trademarks of Tenon Medical, Inc. MAINSAILTM, and SImmetry+™ are also trademarks of Tenon Medical, Inc.Forward-Looking StatementsThis press release contains "forward-looking statements," which are statements related to events, results, activities or developments that Tenon expects, believes or anticipates will or may occur in the future. Forward-looking often contains words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and similar expressions and the negative versions thereof. These forward-looking statements, include, but are not limited to, statements regarding the completion of the Offering, the satisfaction of customary closing conditions related to the Offering and the anticipated use of proceeds therefrom. Such statements are based on Tenon's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. For details on the uncertainties that may cause Tenon's actual results to be materially different than those expressed in any forward-looking statements, please review Tenon's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and updated from time to time in our Form 10-Q filings and in our other public filings on file with the SEC at www.sec.gov statements contain, particularly the information contained in the section entitled "Risk Factors." We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law.Investor Contact
Shannon Devine
MZ North America
203-741-8811
tenon@mzgroup.usSOURCE: Tenon Medical, Inc.View the original press release on ACCESS NewswireOriginal: Tenon Medical, Inc. Announces Pricing of $4.2 Million Public Offering

TNON................................https://stockcharts.com/sc3/ui/?s=TNON&p=w&b=5&g=0&id=p86431144783

$0.87+ 😃

$TNON 💹

Tenon(R) Medical Reports First Quarter 2026 Financial ResultsMay 12, 2026 4:05 PM
ACCESS Newswire~ First Quarter 2026 Revenue of $1.4 Million, an Increase of Approximately 90% Compared to Prior Year ~~ First Quarter Gross Profit of $0.9 Million, an Increase of Approximately 193% Compared to Prior Year ~~ Gross Margin Expanded Approximately 24 Percentage Points Year-Over-Year to 68.5% ~~ Closed $4.3 Million Senior Convertible Note Private Placement to Fund Commercial Expansion and Product Development ~~ Subsequent to Quarter End The Company Opened a new Center of Excellence Training Center in Tampa, FL, Along with Expansion of the Company's Sales Leadership Throughout the Eastern Region~LOS GATOS, CA / ACCESS Newswire / May 12, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today reported financial results for the first quarter ended March 31, 2026.Financial Results and Business UpdatesFirst Quarter 2026 Results:First quarter revenue of $1.4 million, an increase of approximately 90% compared to $0.7 million in the first quarter of 2025.First quarter gross profit of $0.9 million, an increase of approximately 193% compared to $0.3 million in the first quarter of 2025.Gross margin of 68.5%, a twenty-four percentage point improvement from 44.5% in the first quarter of 2025.Cash and cash equivalents of $4.6 million as of March 31, 2026, compared to $3.8 million as of December 31, 2025.Net loss of $3.5 million, or $0.31 per share, in the first quarter of 2026, compared to a net loss of $3.6 million, or $1.01 per share, in the first quarter of 2025.Strengthened the Company's intellectual property portfolio with multiple Notices of Allowance from the U.S. Patent and Trademark Office for patent applications expected to issue in 2026, building on the ten patents issued in 2025 (five U.S. and five international). The portfolio currently includes 29 issued U.S. patents and 9 issued international patents, along with 31 pending U.S. and foreign applications, further reinforcing protection around the Catamaran® and SImmetry®+ SI Joint Fusion Systems.Closed a private placement of senior convertible promissory notes with institutional and high-net-worth investors for aggregate gross proceeds of $4.3 million. The Company expects to use the net proceeds for commercial expansion, product development, clinical studies, working capital and general corporate purposes.Hosted 21 physicians in targeted training sessions for both Catamaran® and SImmetry® within the first quarter."The first quarter of 2026 reflects the early returns on the strategy we have been executing, broadening our SI joint fusion platform, deepening surgeon engagement, and translating those investments into meaningful top-line growth. We delivered significant first quarter revenue of $1.4 million, up approximately 90% year-over-year, and significant first quarter gross profit of $0.9 million, up approximately 193%, demonstrating both the commercial traction of our Catamaran® and SImmetry®+ systems and the operating leverage we have been working to build." said Steven M. Foster, President and CEO of Tenon Medical, Inc. "Looking ahead, our priorities are clear: drive continued procedure growth across both Catamaran® and SImmetry®+, expand our base of trained surgeons, and maintain the disciplined cost structure that is now showing through in our gross margin and field productivity. With a differentiated multi-approach portfolio, a strengthened balance sheet, and the capital flexibility from our recent financing, we believe Tenon is well positioned to build on this quarter's momentum and deliver increasing value to patients, providers, and stockholders."First Quarter 2026 Financial ResultsRevenue was $1.4 million in the first quarter of 2026, an increase of approximately 90% compared to $0.7 million in the same period of 2025. The increase in revenue for the three months ended March 31, 2026 as compared to 2025 was primarily driven by continued adoption of our Catamaran system, leading to an increase in the number of surgical procedures, and the addition of revenue related to the SImmetry®+ System following the August 2025 acquisition.Gross profit was $0.9 million, or 68.5% of revenue, in the first quarter of 2026, compared to $0.3 million, or 44.5% of revenue, in the first quarter of 2025. The twenty-four percentage point gross margin improvement was primarily driven by higher revenue in the period, driving further absorption of production overhead costs within cost of goods sold.Operating expenses totaled $4.2 million in the first quarter of 2026, compared to $4.0 million in the first quarter of 2025. The increase in the three months ended March 31, 2026 was driven by higher sales and marketing expenses associated with increased commercial activity due to higher revenue and ongoing rollout of the SImmetry®+ System, partially offset by lower research and development expenses.Net loss was $3.5 million, or $0.31 per share, in the first quarter of 2026, compared to a net loss of $3.6 million, or $1.01 per share, in the first quarter of 2025. The year-over-year improvement was largely driven by increased revenue and gross profit, partially offset by higher operating expenses and interest expense related to the convertible notes issued in March 2026.As of March 31, 2026, cash and cash equivalents totaled $4.6 million, compared to $3.8 million at December 31, 2025. In March 2026, the Company closed a private placement of senior convertible notes for gross proceeds of $4.3 million to fund continued commercial expansion, upcoming product launches, clinical studies, working capital and general corporate purposes.First Quarter 2026 Earnings Conference CallManagement will host a conference call at 4:30 p.m. ET (1:30 p.m. PT) today, May 12, 2026, to discuss Tenon's first quarter 2026 financial results, provide a corporate update, and conclude with Q&A with the Company's covering analyst. To participate, please use the following information:Date:Tuesday, May 12, 2026Time:4:30 p.m. Eastern timeDial-in:1-877-407-0792International Dial-in:1-201-689-8263Webcast:TNON Conference CallPlease dial in at least 10 minutes before the start of the call to ensure timely participation.An audio playback of the call will be available through May 26, 2026, on Tenon's Investor Relations website at http://ir.tenonmed.com/ or via telephone replay by dialing 1-844-512-2921 (USA) or 1-412-317-6671 (International). The access code will be 13759830.About Tenon Medical, Inc. Tenon Medical, Inc. is a medical device company founded in 2012 and committed to developing novel technologies for patients suffering from debilitating SI joint pain and dysfunction. The Company markets the Catamaran® and SImmetry+® SI Joint Fusion Systems, which offer a novel, less invasive approach to treating SI joint disease. Together, these platforms uniquely position Tenon with multiple surgical approaches, lateral and inferior-posterior, both designed to be minimally invasive, enable authentic arthrodesis, and supported by robust clinical evidence, including the published prospective Mainsail™ and EVoluSIon™ SI joint fusion studies. These differentiated technologies enable physicians to customize treatment plans through an innovative portfolio spanning SI joint fusion, spinal fusion, and deformity adjuncts, each solution engineered to deliver fusion outcomes more reliably. This multi-platform, multiapproach strategy strengthens Tenon's competitive advantage in the expanding SI joint fusion market and underscores the Company's commitment to delivering proven, durable outcomes for physicians and patients. Tenon is focused on three commercial opportunities in the SI joint market: 1) primary SI joint procedures, 2) revision of failed SI joint implants, and 3) augmenting spinal fusion. For more information, please visit www.tenonmed.com.The Tenon Medical logo shown above, and Catamaran®, PiSIF®, CAT PiSIF®, ETAD®, Posterior Inferior Sacroiliac Fusion®, CAT SIJ Fusion System®, Catamaran SIJ Fusion System®, Catamaran Inferior Posterior Fusion System®, Catamaran Transfixation Fusion System®, Catamaran Transfixation Fusion Device®, SImmetry® are registered trademarks of Tenon Medical, Inc. MAINSAILTM, and SImmetry+ are also trademarks of Tenon Medical, Inc.Safe HarborThis press release contains "forward-looking statements," which are statements related to events, results, activities or developments that Tenon expects, believes or anticipates will or may occur in the future. Forward-looking often contains words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and similar expressions and the negative versions thereof. These forward-looking statements, include, but are not limited to, statements regarding the completion of the Offering, the satisfaction of customary closing conditions related to the Offering and the anticipated use of proceeds therefrom. Such statements are based on Tenon's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. For details on the uncertainties that may cause Tenon's actual results to be materially different than those expressed in any forward-looking statements, please review Tenon's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and updated from time to time in our Form 10-Q filings and in our other public filings on file with the SEC at www.sec.gov, particularly the information contained in the section entitled "Risk Factors." We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law.Investor ContactShannon Devine
MZ North America
203-741-8811
tenon@mzgroup.usTenon Medical, Inc.
Condensed Balance Sheets (Unaudited)
(In thousands, except share data) March 31, December31, 2026 2025 ASSETS Current assets: Cash and cash equivalents $4,607 $3,756 Accounts receivable, net 1,969 1,698 Inventory 806 1,054 Prepaid expenses and other current assets 238 260 Total current assets 7,620 6,768 Property and equipment, net 901 918 Deposits 51 51 Operating lease right-of-use asset 1,389 131 Intangible assets, net 470 485 Goodwill 2,407 2,407 TOTAL ASSETS $12,838 $10,760 Liabilities and Stockholders' EQUITY Current liabilities: Accounts payable $646 $845 Accrued expenses 1,774 1,637 Current portion of accrued commissions 686 590 Current portion of operating lease liability 211 141 Convertible notes 3,480 - Derivative liability 608 - Total current liabilities 7,405 3,213 Accrued commissions, net of current portion 1,392 1,514 Operating lease liability, net of current portion 1,186 - Contingent consideration 960 993 Total liabilities 10,943 5,720 Commitments and contingencies Stockholders' equity: Series A convertible preferred stock, $0.001 par value; 4,500,000 shares authorized at March 31, 2026 and December 31, 2025; 204,159 shares issued and outstanding at March 31, 2026 and December 31, 2025 2,622 2,622 Series B convertible preferred stock, $0.001 par value; 491,222 shares authorized at March 31, 2026 and December 31, 2025; 86,454 shares issued and outstanding at March 31, 2026 and December 31, 2025 452 452 Common stock, $0.001 par value; 130,000,000 shares authorized at March 31, 2026 and December 31, 2025; 11,296,378 and 10,851,273 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively 11 11 Additional paid-in capital 83,588 83,257 Accumulated deficit (84,778) (81,302 Total stockholders' equity 1,895 5,040 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $12,838 $10,760 Tenon Medical, Inc.
Condensed Statements of Operations and Comprehensive Loss (Unaudited)
(In thousands, except per share data) Three Months Ended March 31, 2026 2025 Revenue $1,379 $726 Cost of revenue 434 403 Gross Profit 945 323 Operating Expenses Research and development 662 691 Sales and marketing 1,858 1,647 General and administrative 1,705 1,662 Total Operating Expenses 4,225 4,000 Loss from Operations (3,280) (3,677) Other (Expense) Income, net Gain on investments 25 61 Interest expense (176) - Other expense (45) - Total Other (Expense) Income, net (196) 61 Net Loss $(3,476) $(3,616)Net Loss Per Share of Common Stock Basic and diluted $(0.31) $(1.01) Weighted Average Shares of Common Stock Outstanding Basic and diluted 11,268 3,597 SOURCE: Tenon Medical, Inc.View the original press release on ACCESS NewswireOriginal: Tenon(R) Medical Reports First Quarter 2026 Financial Results

Tenon Medical, Inc. Sets Date for First Quarter 2026 EarningsMay 1, 2026 8:00 AM
ACCESS NewswireLOS GATOS, CA / ACCESS Newswire / May 1, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today announced plans to release financial results for the first quarter ended March 31, 2026 after market close on Tuesday, May 12, 2026. The Company will also hold a conference call on the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with its covering analysts.Date:Tuesday, May 12, 2026Time:4:30 p.m. Eastern timeDial-in:1-877-407-0792International Dial-in:1-201-689-8263Webcast:TNON Conference CallPlease dial in at least 10 minutes before the start of the call to ensure timely participation.An audio playback of the call will be available through May 26, 2026, on Tenon's Investor Relations website at http://ir.tenonmed.com/ or via telephone replay by dialing 1-844-512-2921 (USA) or 1-412-317-6671 (International). The access code will be 13759830.About Tenon Medical, Inc. Tenon Medical, Inc. is a medical device company founded in 2012 and committed to developing novel technologies for patients suffering from debilitating SI joint pain and dysfunction. The Company markets the Catamaran® and SImmetry+® SI Joint Fusion Systems, which offer a novel, less invasive approach to treating SI joint disease. Together, these platforms uniquely position Tenon with multiple surgical approaches, lateral and inferior-posterior, both designed to be minimally invasive, enable authentic arthrodesis, and supported by robust clinical evidence, including the published prospective Mainsail™ and EVoluSIon™ SI joint fusion studies. These differentiated technologies enable physicians to customize treatment plans through an innovative portfolio spanning SI joint fusion, spinal fusion, and deformity adjuncts, each solution engineered to deliver fusion outcomes more reliably. This multi-platform, multiapproach strategy strengthens Tenon's competitive advantage in the expanding SI joint fusion market and underscores the Company's commitment to delivering proven, durable outcomes for physicians and patients. Tenon is focused on three commercial opportunities in the SI joint market: 1) primary SI joint procedures, 2) revision of failed SI joint implants, and 3) augmenting spinal fusion. For more information, please visit www.tenonmed.com.The Tenon Medical logo shown above, and Catamaran®, PiSIF®, CAT PiSIF®, ETAD®, Posterior Inferior Sacroiliac Fusion®, CAT SIJ Fusion System®, Catamaran SIJ Fusion System®, Catamaran Inferior Posterior Fusion System®, Catamaran Transfixation Fusion System®, Catamaran Transfixation Fusion Device®, SImmetry® are registered trademarks of Tenon Medical, Inc. MAINSAILTM, and SImmetry+ are also trademarks of Tenon Medical, Inc.Investor ContactShannon Devine
MZ North America
203-741-8811
tenon@mzgroup.usSOURCE: Tenon Medical, Inc.View the original press release on ACCESS NewswireOriginal: Tenon Medical, Inc. Sets Date for First Quarter 2026 Earnings

Tenon(R) Medical Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 19, 2026 4:05 PM
ACCESS Newswire~ Fourth Quarter 2025 Revenue of $1.5 Million, a 92% Increase Compared to Prior Year ~~ Record Full Year 2025 Revenue of $3.9 Million, a 20% Increase compared to Prior Year, Driven by Strong Second Half Momentum ~~ Record Full Year 2025 Gross Profit of $2.4 Million, a 38% Increase Compared to Prior Year ~~ Secured FDA 510(k) Clearance For its Next-Generation SImmetry®+ SI Joint Fusion System ~~ Completed Initial SImmetry®+ Procedures at Centers of Excellence, Advancing Commercial Rollout and Supporting Early Surgeon Adoption ~LOS GATOS, CA / ACCESS Newswire / March 19, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today reported financial results for the fourth quarter and year ended December 31, 2025.Financial Results and Business UpdatesFourth Quarter 2025 Results:Record revenue of $1.5 million, an increase of 92% compared to $0.8 million in the fourth quarter of 2024.Gross profit of $1.0 million, an increase of 188% compared to $0.4 million in the fourth quarter of 2024.Gross margin of 69%, a twenty-three percentage point improvement from 46% in the fourth quarter of 2024.Full Year 2025 Results:Record revenue of $3.9 million, a 20% increase compared to $3.3 million in 2024.Gross profit of $2.4 million, a 38% increase compared to $1.7 million in 2024.Gross margin of 60%, an eight percentage point improvement from 52% in 2024.Tenon received FDA 510(k) clearance for its next-generation SImmetry®+ SI Joint Fusion System, expanding its portfolio to include a complementary lateral approach. This clearance broadens the Company's addressable market and enhances its ability to support diverse surgeon preferences and patient anatomies.The Company completed a $2.85 million At-The-Market PIPE financing in Q4 2025 to strengthen its balance sheet and support strategic growth initiatives. The additional capital provides flexibility to advance product launches, expand commercial operations, and fund clinical development efforts.Tenon successfully completed initial SImmetry®+ procedures at Centers of Excellence, marking an important step in the system's commercial rollout. Early clinical experience reinforces surgeon confidence and supports broader market expansion in the quarters ahead.Hosted 24 physicians in targeted training sessions for both Catamaran® and SImmetry® within the fourth quarterSubsequent UpdatesAnnounced the closing of private placement of senior convertible notes offering for gross proceeds of $4.3 million in March 2026. Net proceeds are expected to fund continued commercial expansion, upcoming product launches, clinical studies, working capital and general corporate purposes.Announced the expansion of our intellectual property portfolio with multiple Notices of Allowance from the U.S. Patent and Trademark Office, further strengthening protection around our Catamaran® and SImmetry® technologies and bringing our global estate to 29 issued U.S. patents, nine international patents, and 31 pending applications. We believe that this enhanced IP position reinforces the defensibility of our platform and supports our long-term growth and competitive differentiation as adoption continues to accelerate."Our fourth quarter marked a significant period for Tenon, highlighted by FDA clearance of SImmetry®+, successful early clinical experience, record procedure growth, and continued commercial expansion," said Steve Foster, President and Chief Executive Officer of Tenon Medical. "We not only broadened our SI joint fusion platform to support multiple surgical approaches, but we also strengthened our balance sheet and, subsequent to quarter end, expanded our intellectual property estate, further reinforcing the long-term defensibility of our technology.""As we enter 2026, we are building on this momentum with accelerating adoption, improving field productivity, and a tightening cost structure that enhances operating leverage. With a differentiated portfolio, growing surgeon engagement, and a strengthened competitive position, we believe Tenon is well positioned to drive sustainable growth and deliver increasing value to patients, providers, and shareholders." concluded Mr. Foster.Fourth Quarter & Full Year 2025 Financial ResultsRevenue was $1.5 million in the fourth quarter of 2025, an increase of 92% compared to $0.8 million in the same period of 2024. Revenue for the year ended December 31, 2025, was $3.9 million, an increase of 20% compared to $3.3 million in the year ended December 31, 2024. The increase in revenue for the year ended December 31, 2025 as compared to 2024 was primarily due to an increase in the number of surgical procedures in the back half of 2025 across both the Catamaran® and SImmetry®+ platforms, driven primarily by the adoption of new physician users.Gross profit was $1.0 million, or 69% of revenue, in the fourth quarter of 2025, compared to $0.4 million, or 46% of revenue, in the fourth quarter of 2024. For the year ended December 31, 2025, gross profit was $2.4 million, or 60% of revenues, compared to $1.7 million, or 52% of revenue, for the year ended December 31, 2024. The eight percentage point gross margin improvement for the year ended December 31, 2025 was primarily driven by higher revenue in the second half of 2025, driving further absorption of fixed costs within cost of goods sold.Operating expenses totaled $3.9 million in the fourth quarter of 2025, compared to $3.5 million in the fourth quarter of 2024. For the year ended December 31, 2025, operating expenses totaled $15.2 million compared to $15.5 million in the prior year period. The increase in the three months ended December 31, 2025, was primarily due to higher variable expenses within sales and marketing, driven by increased revenue in the period, while the decrease for the year ended December 31, 2025 was due to reduced general and administrative expenses, partially offset by increased sales and marketing investment to support increased sales and continued commercial expansion.Net loss was $2.8 million, or $0.29 per share, in the fourth quarter of 2025, compared to a net loss of $3.1 million, or $0.98 per share, in the fourth quarter of 2024. For the year ended December 31, 2025, net loss was $12.6 million, or $1.70 per share, compared to a net loss of $13.7 million, or $11.26 per share, in the same year ago period. The year-over-year improvement in both periods was largely driven by increased revenue and reduced operating expenses fortifying operating leverage.As of December 31, 2025, cash and cash equivalents totaled $3.8 million, compared to $6.5 million at December 31, 2024. The Company had no outstanding debt as of quarter-end, positioning it to continue executing on its strategic initiatives, including the development and launch of the acquired SiVantage assets and expanding the commercial team.Fourth Quarter 2025 Earnings Conference CallManagement will host a conference call at 4:30 p.m. ET (1:30 p.m. PT) today, March 19, 2026, to discuss Tenon's fourth quarter and full year 2025 financial results, provide a corporate update, and conclude with Q&A with the Company's covering analyst. To participate, please use the following information:Date:Thursday, March 19, 2026Time:4:30 p.m. Eastern timeDial-in:1-877-407-0792International Dial-in:1-201-689-8263Webcast:TNON Conference CallPlease dial in at least 10 minutes before the start of the call to ensure timely participation.An audio playback of the call will be available through April 22, 2026, on Tenon's Investor Relations website at http://ir.tenonmed.com/ or via telephone replay by dialing 1-844-512-2921 (USA) or 1-412-317-6671 (International). The access code will be 13758268.About Tenon Medical, Inc. Tenon Medical, Inc. is a medical device company founded in 2012 and committed to developing novel technologies for patients suffering from debilitating SI joint pain and dysfunction. The Company markets the Catamaran® and SImmetry+® SI Joint Fusion Systems, which offer a novel, less invasive approach to treating SI joint disease. Together, these platforms uniquely position Tenon with multiple surgical approaches, lateral and inferior-posterior, both designed to be minimally invasive, enable authentic arthrodesis, and supported by robust clinical evidence, including the published prospective Mainsail™ and EVoluSIon™ SI joint fusion studies. These differentiated technologies enable physicians to customize treatment plans through an innovative portfolio spanning SI joint fusion, spinal fusion, and deformity adjuncts, each solution engineered to deliver fusion outcomes more reliably. This multi-platform, multi-approach strategy strengthens Tenon's competitive advantage in the expanding SI joint fusion market and underscores the Company's commitment to delivering proven, durable outcomes for physicians and patients. Tenon is focused on three commercial opportunities in the SI joint market: 1) primary SI joint procedures, 2) revision of failed SI joint implants, and 3) augmenting spinal fusion. For more information, please visit www.tenonmed.com.The Tenon Medical logo shown above, and Catamaran®, PiSIF®, CAT PiSIF®, ETAD®, Posterior Inferior Sacroiliac Fusion®, CAT SIJ Fusion System®, Catamaran SIJ Fusion System®, Catamaran Inferior Posterior Fusion System®, Catamaran Transfixation Fusion System®, Catamaran Transfixation Fusion Device®, SImmetry® are registered trademarks of Tenon Medical, Inc. MAINSAILTM, and SImmetry+ are also trademarks of Tenon Medical, Inc.Safe HarborThis press release contains "forward-looking statements," which are statements related to events, results, activities or developments that Tenon expects, believes or anticipates will or may occur in the future. Forward-looking often contains words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and similar expressions and the negative versions thereof. These forward-looking statements, include, but are not limited to, statements regarding the completion of the Offering, the satisfaction of customary closing conditions related to the Offering and the anticipated use of proceeds therefrom. Such statements are based on Tenon's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. For details on the uncertainties that may cause Tenon's actual results to be materially different than those expressed in any forward-looking statements, please review Tenon's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and updated from time to time in our Form 10-Q filings and in our other public filings on file with the SEC at www.sec.gov, particularly the information contained in the section entitled "Risk Factors." We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law.Investor ContactShannon Devine
MZ North America
203-741-8811
tenon@mzgroup.usTenon Medical, Inc.
Condensed Balance Sheets (Unaudited)
(In thousands, except share data) December 31, December 31, 2025 2024 ASSETS Current assets: Cash and cash equivalents $3,756 $6,535 Accounts receivable, net 1,698 863 Inventory, net 1,054 606 Prepaid expenses and other current assets 260 206 Total current assets 6,768 8,210 Property and equipment, net 918 752 Deposits 51 51 Operating lease right-of-use asset 131 399 Deferred offering costs - 431 Intangible assets, net 485 - Goodwill 2,407 - TOTAL ASSETS $10,760 $9,843 Liabilities and Stockholders' EQUITY Current liabilities: Accounts payable $845 $369 Accrued expenses 1,637 910 Current portion of accrued commissions 590 303 Current portion of operating lease liability 141 287 Total current liabilities 3,213 1,869 Accrued commissions, net of current portion 1,514 1,862 Operating lease liability, net of current portion - 141 Contingent consideration 993 - Total liabilities 5,720 3,872 Stockholders' equity: Series A convertible preferred stock, $0.001 par value; 4,500,000 shares authorized at December 31, 2025 and 2024; 204,159 and 256,968 shares issued and outstanding at December 31, 2025 and 2024, respectively 2,622 3,300 Series B convertible preferred stock, $0.001 par value; 491,222 shares authorized at December 31, 2025 and 2024; 86,454 shares issued and outstanding at December 31, 2025 and 2024, respectively 452 452 Common stock, $0.001 par value; 130,000,000 shares authorized at December 31, 2025 and 2024; 10,851,273 and 3,138,804 shares issued and outstanding at December 31, 2025 and 2024, respectively 11 3 Additional paid-in capital 83,257 70,962 Accumulated deficit (81,302) (68,746)Total stockholders' equity 5,040 5,971 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $10,760 $9,843 Tenon Medical, Inc.
Condensed Statements of Operations and Comprehensive Loss (Unaudited)
(In thousands, except per share data) Years EndedDecember 31, 2025 2024 Revenue $3,944 $3,277 Cost of sales 1,586 1,566 Gross Profit 2,358 1,711 Operating Expenses General and administrative 6,975 7,765 Sales and marketing 6,026 5,109 Research and development 2,149 2,603 Total Operating Expenses 15,150 15,477 Loss from Operations (12,792) (13,766) Other Income (Expense) Gain on investments 236 183 Interest expense - (34)Other expense, net - (56)Total Other Income (Expense), net 236 93 Net Loss $(12,556) $(13,673)Net Loss Per Share of Common Stock Basic and diluted $(1.70) $(11.26) Weighted-Average Shares of Common Stock Outstanding Basic and diluted 7,384 1,214 Statements of Comprehensive Loss: Net loss $(12,556) $(13,673)Foreign currency translation adjustment - 46 Total Comprehensive Loss $(12,556) $(13,627)SOURCE: Tenon Medical, Inc.View the original press release on ACCESS NewswireOriginal: Tenon(R) Medical Reports Fourth Quarter and Full Year 2025 Financial Results

Tenon(R) Medical Strengthens Intellectual Property Portfolio with Strategic Patent ExpansionFebruary 18, 2026 8:35 AM
ACCESS NewswireExpanded Global Portfolio Enhances Competitive Position and Supports Long-Term Growth StrategyLOS GATOS, CA / ACCESS Newswire / February 18, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today announced a strategic expansion of its U.S. intellectual property portfolio following receipt of Notices of Allowance from the United States Patent and Trademark Office (USPTO) for multiple patent applications expected to issue in 2026. These newly allowed claims will further strengthen the Company's growing patent portfolio and build upon the (10) ten patents issued in 2025, including (5) five issued by the USPTO and (5) five issued internationally.These patents strengthen protection around key systems and methods underlying the Company's Catamaran® SI Joint Fusion System and further reinforce Tenon's commitment to innovation in sacro-pelvic fusion. In addition, the Company anticipates the issuance of additional patent applications in 2026, which would further expand and enhance its growing intellectual property portfolio.The Company continues to diversify its intellectual property through the recent strategic asset acquisition of SIVantage®'s SImmetry® and SImmetry®+ lateral SI joint fusion systems. Supported by (16) sixteen issued U.S. patents, the SImmetry and SImmetry+ sacroiliac joint fusion systems bring a well-established clinical foundation and a differentiated fusion approach that complements and expands Tenon's existing Catamaran platform.Backed by a robust innovation pipeline designed to drive continued procedure adoption and revenue growth, the Company expects to further expand and strengthen the intellectual property protection surrounding its Catamaran and SImmetry+ SI Joint implant systems. The portfolio currently includes (29) twenty-nine issued U.S. patents and (9) nine issued international patents, along with (31) thirty-one pending U.S. and foreign patent applications."Our intellectual property strategy is foundational to Tenon's long-term growth," said Richard Ginn, Chief Operating Officer and Co-Founder of Tenon Medical. "Building and protecting a strong global patent portfolio ensures that the innovation we are pioneering - and delivering to physicians and their patients - remains differentiated and defensible in a competitive market. Efforts such as these further solidify our patent position, safeguard our technology platform, strengthen our competitive standing within the industry, and underscore our commitment to advancing less invasive sacroiliac joint solutions. Protecting our innovation today enables us to invest confidently in the next generation of technologies that will bring value to our shareholders, but more importantly continue to redefine care for patients suffering from sacro-pelvic disorders as well."About Tenon Medical, Inc.Tenon Medical, Inc., a medical device company formed in 2012, has developed The Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Since the national launch of the Catamaran SI Joint Fusion System in October 2022, Tenon is focused on three commercial opportunities with its System in the SI Joint market which include: 1) Primary SI Joint procedures, 2) Revision procedures of failed SI Joint implants and 3) Augmenting spinal fusion. For more information, please visit www.tenonmed.com.The Tenon Medical logo shown above, and Catamaran®, PiSIF®, CAT PiSIF®, ETAD®, Posterior Inferior Sacroiliac Fusion®, CAT SIJ Fusion System®, Catamaran SIJ Fusion System®, Catamaran Inferior Posterior Fusion System®, Catamaran Transfixation Fusion System®, Catamaran Transfixation Fusion Device®, SImmetry® are registered trademarks of Tenon Medical, Inc. MAINSAILTM, and SImmetry+ are also trademarks of Tenon Medical, Inc.Safe HarborThis press release contains "forward-looking statements," which are statements related to events, results, activities, or developments that Tenon expects, believes, or anticipates will or may occur in the future. Forward-looking often contains words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," "aims," and similar expressions and the negative versions thereof. Such statements are based on Tenon's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain, and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of numerous factors. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, please review our Annual Report on 10-K on file with the Securities and Exchange Commission at www.sec.gov, particularly the information contained in the section entitled "Risk Factors". We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law.Investor ContactShannon Devine
MZ North America
203-741-8811
tenon@mzgroup.usSOURCE: Tenon Medical, Inc.View the original press release on ACCESS NewswireOriginal: Tenon(R) Medical Strengthens Intellectual Property Portfolio with Strategic Patent Expansion

TNON............................................................p/m

Tenon Medical, Inc. Sets Date for Fourth Quarter and Full Year 2025 Earnings, Reaffirms Expected RevenuesFebruary 5, 2026 8:30 AM
ACCESS NewswireFourth Quarter 2025 Revenue of $1.45 to $1.48 Million, representing growth of ~90% year over yearFull Year 2025 Revenue of $3.91 to $3.94 Million, representing growth of ~20% year over yearLOS GATOS, CA / ACCESS Newswire / February 5, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today announced plans to release financial results for the fourth quarter and full year 2025 ended December 31, 2025 after market close on Thursday, March 19, 2026. The Company will also hold a conference call on the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with its covering analysts.Date:Thursday, March 19, 2026Time:4:30 p.m. Eastern timeDial-in:1-877-407-0792International Dial-in:1-201-689-8263Webcast:TNON Conference CallPlease dial in at least 10 minutes before the start of the call to ensure timely participation.An audio playback of the call will be available through April 2, 2026, on Tenon's Investor Relations website at http://ir.tenonmed.com/ or via telephone replay by dialing 1-844-512-2921 (USA) or 1-412-317-6671 (International). The access code will be 13758268.About Tenon Medical, Inc. Tenon Medical, Inc., a medical device company formed in 2012, has developed The Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Since the national launch of the Catamaran SI Joint Fusion System in October 2022, Tenon is focused on three commercial opportunities with its System in the SI Joint market which include: 1) Primary SI Joint procedures, 2) Revision procedures of failed SI Joint implants and 3) Augmenting spinal fusion. For more information, please visit www.tenonmed.com.The Tenon Medical logo shown above, and Catamaran®, PiSIF®, CAT PiSIF®, ETAD®, Posterior Inferior Sacroiliac Fusion®, CAT SIJ Fusion System®, Catamaran SIJ Fusion System®, Catamaran Inferior Posterior Fusion System®, Catamaran Transfixation Fusion System®, Catamaran Transfixation Fusion Device®, SImmetry® are registered trademarks of Tenon Medical, Inc. MAINSAILTM, and SImmetry+ are also trademarks of Tenon Medical, Inc.Investor ContactShannon Devine
MZ North America
203-741-8811
tenon@mzgroup.usSOURCE: Tenon Medical, Inc.View the original press release on ACCESS NewswireOriginal: Tenon Medical, Inc. Sets Date for Fourth Quarter and Full Year 2025 Earnings, Reaffirms Expected Revenues

Added some $1.31 this morning on news

tnon///////////////////////////////////////////////https://stockcharts.com/h-sc/ui?s=TNON&p=W&b=5&g=0&id=p86431144783

TNON.................................................................................p/m

Tenon Medical(R) Expands Sacro-Pelvic Fusion Portfolio with Strategic Asset Acquisition
~ SiVantage Portfolio Acquisition Enhances Tenon's Sacroiliac Joint Fusion Capabilities with a Unique Multi-Product, Multi-Approach Solution ~

~ Significant Enhancement of Tenon Medical's Commercial Leadership to Accelerate Growth Initiatives ~

~ Reinforces Tenon's Commitment to Fusion-Driven Innovation and Data-Backed Outcomes in a Rapidly Evolving Market ~

LOS GATOS, CA / ACCESS Newswire / August 1, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical technology company dedicated to transforming care for patients with sacroiliac joint (SIJ) disorders, today announced it has acquired sacroiliac (SI) joint specific assets from SiVantage, a privately held startup company based in Tampa, Florida. This strategic asset acquisition includes SiVantage's SImmetry® and SImmetry+™ technologies expanding Tenon's SI portfolio across multiple approaches to the variable sacro pelvic anatomy. These differentiated technologies enable physicians to customize treatment plans for their patients using novel authentic fusion products backed by clinical data.

Transaction Highlights

Transaction moves critical technologies, intellectual property, and commercial leadership of SiVantage to Tenon Medical.
Core technology products are expected to contribute to revenue immediately.
Enhanced product pipeline is significantly strengthened, accelerating innovation and market readiness.
Supported by extensive clinical data, the integrated platform demonstrates a proven record of safety and performance.
Tenon is now a multi-product, multi-approach sacro-pelvic organization.
This strategic acquisition enhances Tenon's unique ability to meet the evolving needs of physicians and their patients.
SiVantage Co-Founders Wyatt Geist and Nate Grawey are joining Tenon's management team as Chief Innovations Officer and Chief Commercial Officer, respectively - bringing decades of medical device experience and relationships, further strengthening the Company's commercial leadership.
The Company now offers a modern, integrated portfolio spanning SI joint fusion, spinal fusion, and deformity adjuncts-each engineered to help deliver reliable fusion outcomes. While others focus on fixation, Tenon prioritizes what truly matters: biologic fusion.
Tenon's implants and instruments are designed not just to stabilize, but to actively promote bone healing, minimize loosening, and restore lasting structural stability.
Transaction structure includes a modest upfront cash component and an equity issuance representing a percentage of shares outstanding, with the majority of total consideration contingent upon achieving future performance milestones.
Integration activities will commence immediately and will be completed in Q4 2025.
Management Commentary

"The sacro pelvic fusion space is evolving very quickly. As our physician customers define their needs, Tenon Medical will deliver innovative solutions backed by clinical data to emerge as a leader in this high growth space." said Steve Foster, Chief Executive Officer of Tenon Medical. "With the addition of extraordinary people and a pipeline of innovative solutions, Tenon is now a multi-product and multi-approach sacro-pelvic organization that is poised for growth. We are laser focused on innovative solutions that deliver authentic fusion principals in a format with a strong safety profile backed by biomechanical and clinical data."

Wyatt Geist, CEO and Co-Founder of SiVantage and a recognized entrepreneur in the space with over one hundred patents to his name stated, "I am extremely excited to work with this data driven team to deliver exciting innovative technologies. It became clear in our early discussions with Tenon that we shared visions and values focused on collaborating with ethical partners to redefine sacroiliac fusion and deliver safe, effective solutions that enhance patient outcomes and provide unparalleled surgical reproducibility."

Nate Grawey, President and Co-Founder of SiVantage added, "Tenon's platform is THE perfect fit for SImmetry and the soon to be launched SImmetry+. This combined company will offer a differentiated portfolio that physicians want, administrators approve and payors value."

About Tenon Medical, Inc.

Tenon Medical, Inc., a medical device company formed in 2012, has developed The Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran™ Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Since the national launch of the Catamaran SI Joint Fusion System in October 2022, Tenon is focused on three commercial opportunities with its System in the SI Joint market which include: 1

TNON......................................................................p/m

Under the $...

TNON daily

You want strong merger speculation? Take a look at $tglo and Delfin LNG. Sorry for the spam, but thank me later.

Took a chunk yesterday 1.60's and another nibble this morning. Holding for the potential merger / buyout.
GL

https://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=&insttype=&symb=tnon&x=35&y=11&time=3&startdate=1%2F4%2F1999&enddate=12%2F19%2F2024&freq=8&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=4&maval=9&uf=8&lf=16&lf2=512&lf3=65536&type=4&style=320&size=4&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11

and

https://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=&insttype=Stock&symb=tnon&x=35&y=7&time=2&startdate=1%2F4%2F1999&enddate=12%2F19%2F2024&freq=9&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=4&maval=9&uf=8&lf=16&lf2=512&lf3=65536&type=4&style=320&size=4&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11


and

TNON daily
TNON

$TNON gap test time.
TNON Daily

Just took a bite this morning. Will take some lower as well if it gets there. Thinking merger by the end of the year. Just my WAG.

GL & cheers Glenn. Always appreciate your charts.

Here's my daily...

TNON daily

Under 1.50 would be sweet but not sure it'll happen.

TNON.......................................................https://stockcharts.com/h-sc/ui?s=TNON&p=W&b=5&g=0&id=p86431144783

TNON 10k https://www.otcmarkets.com/filing/html?id=18314825&guid=ieB-kq34plV0Rch

Major dilution

$TNON: Greedy ass pigs really.............

Thats why these things fizzle cuz management wants to pocket for themselves.
Put out something promising and then rake it in.

Greedy ass pigs............. just ride their coattails as long enough and then hop off so they don't screw you.

GO $TNON

Why would they sell shares for $2?

They are doing a direct sale to an investor. LSEG has a price target of $7.50. It closed at $3.75. I wonder how the market will react to this $2 offering.

#DDAmanda Video: $TNON: Gain: +291% #1 Early Alert Stock Finder



Z

Round 2 as $3.30s bottom for another flip

$TNON: Wow....... it actually tapped $1.50 ?????

Wish I had a bid down there that low.

Nice grab to whoever got those.

CONGRATS


GO $TNON

any reason warrants aren't up more?

$4.60 would wait for markets open now see if $3.30-3.40 retest holds 

tron............................................https://stockcharts.com/h-sc/ui?s=TNON&p=W&b=5&g=0&id=p86431144783

$5.04 + 410%

Nice run $4.81 + 390%

$TNON: Good call..............

I saw this on my radar yesterday at the open but didn't make much of it as it petered out.
And now look.............. almost tapped $4 from yesterdays bottom of $1.

So you never know............ keep up the good work

GO $TNON

TNON could enter a new universe!💯

TNON.................................................OOOOOOOOOOOOOOOOPS

Tenon Medical(R) Announces FDA Clearance of Catamaran(R) SI Joint Fusion System for New Indication to Augment Spinal Fusion
~ Achieves Significant Milestone with Expanded Use Indication, Opens Sizable New SI Market Opportunity ~

LOS GATOS, CA / ACCESS Newswire / March 24, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, announced today that the U.S. Food and Drug Administration (FDA) has provided clearance of an expanded indication for the Catamaran® SI Joint Fusion System (the "Catamaran") for use in augmenting thoracolumbar fusion. With this approval, the Catamaran is now indicated to treat the SI joint as either a stand-alone treatment or to augment a spinal fusion.

"The FDA has cleared the Catamaran SI Joint Fusion System for use in augmenting thoracolumbar fusion," commented Richard Ginn, Co-Founder and Chief Technology Officer of Tenon Medical. "This is a significant milestone for Tenon Medical, as this new indication opens the door to a previously untapped market. The Catamaran stands out due to its unique design, providing physicians with greater flexibility in treating patients."

"Recognition from the FDA of Catamaran's use to augment spinal fusion has been a long-term goal of Tenon during the development of the Catamaran SI Joint Fusion System," said Steve Foster, Chief Executive Officer of Tenon Medical. "As our clinical experience grows and the data from our MAINSAIL clinical trial emerges, it is clear that we achieve an authentic fusion of the SI Joint in a safe, reliable and efficient manner. We believe this can be an important tool in the complex spine surgeon arsenal to support the base of a multi-level fusion. This important achievement instills further confidence that the Catamaran delivers on its pr

$1. 60s History will repeat.. tooMuch debt here but nice jump from bottom

You nailed that one.

...........................................thx...........................................out

$1.87 if history repeats over and over won't stay up long. Start cashing out gains and don't look back

Tenon Medical(R) Receives Approval for Notice of Allowance from the European Patent Office
LOS GATOS, CA / ACCESS Newswire / March 10, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, announced today the Company has been notified by the European patent office that two additional patents directed to the novel Catamaran SI Joint Fixation Device have been approved for grant of a European patent within the European Community.

"The Tenon Medical team is pleased to receive recognition from the European Community for our novel Catamaran® SI joint prostheses," commented Richard Ginn, Co-Founder and Chief Technology Officer of Tenon Medical. "Receiving notification of approval for two additional patents by the European patent office reinforces Tenon's increasingly robust patent position worldwide as well as our commitment to continued innovation."

TNON............................https://stockcharts.com/h-sc/ui?s=TNON&p=W&b=5&g=0&id=p86431144783

Old news recycled over and over

Good luck.

Tenon Medical(R) Announces Issuance of Three U.S. Patents
Further Solidifies International Patent Portfolio and Underscores the Company's Commitment to Innovation of SI Joint Stabilization Systems and Methods

LOS GATOS, CA / ACCESSWIRE / October 17, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced the issuance of U.S. Patent Nos. 12,115,075, 12,115,076 and 12,115,077.

U.S. Patent Nos. 12,115,075 and 12,115,076, both entitled "Sacroiliac Joint Stabilization Prostheses", are directed to Tenon's enhanced Catamaran® prostheses that include unique drug delivery compositions, which enhance sealing of the prostheses in SI joint bone structures and bone growth about and within the prostheses when the prostheses are implanted in a SI joint.

U.S. Patent No. 12,115,077, entitled "Systems, Apparatus and Methods for Stabilizing Sacroiliac Joints", is directed to SI joint prostheses with unique structures and configurations to correct failed SI joint stabilization with alternative commercial SI joint implants without requiring removal of the failed implant.

The three (3) U.S. patents further enhance the Company's growing patent portfolio for its Catamaran® SI Joint Fusion System, which now comprises twelve (12) issued U.S. and foreign (International) patents, and twenty-three (23) pending U.S. and foreign patent applications.

"We are pleased with the USPTO's recognition of the novel Catamaran® SI joint prostheses that will provide a best in class solution to specifically address the need for revision of other ineffective SI joint devices," commented Richard Ginn, Co-Founder and Chief Technology Officer of Tenon Medical. He concluded, "The issuance of these patents reinforces Tenon's focus on innovation while simultaneously protecting our technology platform which strengthens our competitive position in the industry."

patent news https://finviz.com/quote.ashx?t=TNON&ty=c&ta=1&p=d